Skip to main navigation Skip to search Skip to main content

Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab

  • B. A. Khaw
  • , T. Yasuda
  • , H. K. Gold
  • , R. C. Leinbach
  • , J. A. Johns
  • , M. Kanke
  • , M. Barlai-Kovach
  • , H. W. Strauss
  • , E. Haber

Research output: Contribution to journalArticlepeer-review

137 Scopus citations

Abstract

Indium-111 monoclonal antimyosin Fab scintigraphy was used to detect myocardial necrosis in 52 of 54 patients (96.3%) with acute myocardial infarction. Infarcts were visualized when coronary arteries were presistently occluded (n=10), became patent after thrombolysis (n=33), or became patent after spontaneous reperfusion (n=7). Posteroinferolateral visualizations were obtained in two patients with clinical and enzymatic evidence of infarction but normal electrocardiograms. Of the two patients in whom no infarcts were visualized, one had an anterior myocardial infarct. This patient underwent successful thrombolytic therapy, with attendant minimization of creatine kinase release. The other patient had a small, nonreperfused inferior myocardial infarct. Five patients with a history of remote infarction and acute necrosis showed antimyosin uptake only in regions concordant with the acute episodes of infarction, and radiolabeled antimyosin Fab localized in neither old infarcts nor normal, noninfarcted myocardium. Antimyosin Fab scintigraphy, thus appears to be a highly specific means of delineating necrotic myocardium, at least in this limited and selected group of patients.

Original languageEnglish
Pages (from-to)1671-1678
Number of pages8
JournalJournal of Nuclear Medicine
Volume28
Issue number11
StatePublished - 1987
Externally publishedYes

Fingerprint

Dive into the research topics of 'Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab'. Together they form a unique fingerprint.

Cite this